Consequently, the use of BDNF-derepressing AntagoNATs has significant therapeutic potential in PD (Mogi et al., 1999; Parain et al., 1999; Magistri et al., 2012; Modarresi et al., 2012; Wahlestedt, 2013; Halley et al., 2014). The gene discussed is BDNF; the disease is Parkinson disease.